Manufactured by:ProteoGenix
Save 20%RUO

Anti-CoV-S[679-833]-F7 antibody

Anti-CoV-S[679-833]-F7 antibody from ProteoGenix; catalogue PTXCOV-A516B; research use only.

SKU:
ABM133515-1
Manufacturer SKU
PTXCOV-A516B
Product type
Primary Antibodies
TargetRecombinant CoV-S[679-833] fragment
Expression systemMammalian
Purity90%

Manufacturer provenance

Manufactured by:
ProteoGenix
Sold by:
ABMIUM
Fulfilled from:
Manufacturer facility or confirmed fulfilment location

Know who made it. See the evidence. Buy through one marketplace.

Product description

General information on Anti-CoV-S[679-833]-F7 antibody

The anti-CoV-S[679-833]-F7 antibody targets the CoVs[679-833] region of the spike glycoprotein of SARS-CoV-2. This region is predicted to represent the border between the S1 and S2 subunits of the complex transmembrane protein and to contain a furin cleavage site. This site is deemed crucial for the pathology caused by the new coronavirus strain. Absent from the genomic sequences of other strains of the same family, the site represents the cleavage point between the two subunits resulting in the exposure of the S2 subunit which, in turn, catalyzes the membrane fusion between the viral particles and human epithelial cells.
This antibody is suitable to investigate the mechanisms of membrane fusion in SARS-CoV-2 and to determine if antibodies able to block this region prevent viral internalization and, subsequently, arrest the infection process and prevent the onset of the COVID-19 disease.
Anti-CoV-S[679-833]-F7 is a fully human IgG antibody developed using our exclusive COVID-19 human antibody library (LiAb-SFCOVID-19™) comprising the immune repertoire of dozens of COVID-19 survivors with a clonal diversity of 1.2 x 1010. The huge clonal diversity from immune repertories tied to the screening capacity of phage display ensures an optimal diversity of the most relevant binders with therapeutic and diagnostic potential.
The strong affinity of this phage display-derived antibody towards the CoVs[679-833] antigen was tested and validated using enzyme-linked immunosorbent assay (ELISA). Additionally, no cross-reactions were detected against other regions of the spike glycoprotein of SARS-CoV-2. The IgG conformation of this molecule was also swiftly expressed in our transient expression system XtenCHO™ – a highly productive mammalian cell line obtained by engineering CHO cells for optimal productivity.

ProteoGenix catalogue number PTXCOV-A516B. For research use only.

Target: Recombinant CoV-S[679-833] fragment; Clonality: Monoclonal Antibody; Expression system: Mammalian; Purity: 90%; Molecular weight: 150kDa; Buffer: PBS, pH7,5.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet

Key facts & specifications
Clonality
Monoclonal
Isotype
IgG1
Source organism
Human
Molecular weight
150kDa
Form / buffer
Liquid
Technical note
For research use and in vitro diagnostic only. Not suitable for human use.
Identifiers & database references
Manufacturer SKU
PTXCOV-A516B
Storage, stability & shipping
Storage conditions
4°C for short term; -20°c or -80°C for long term
Shipped at
Blue ice (+4°C)
Compliance & documents
ISO certifications
ISO 9001:2023, ISO 14001: 2023
Datasheet
Open datasheet
Frequently asked questions
Who manufactured this product?

This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.

Can ABMIUM ship this product internationally?

ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.

Can I check suitability before ordering?

Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.

Is this product for clinical use?

Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.

ProteoGenix
£235.00£188.00